Covidien

An exciting year for the medical technology industry

Monday, December 19, 2016

The Pulse on Global Trials by Matthew Howes

In the medical technology industry, 2016 has been an exciting year for R&D. From the development of naturally moving prosthetic limbs that are controlled by the brain to the use of a needle-free vaccine delivery device in Zika trials, medical devices are becoming a major focus in the advancement of human health.

[Read More]

Optimal Strategix Group launches study matching app

Wednesday, September 16, 2015

Optimal Strategix Group (OSG), based in Newtown, Pa., has launched its CAVII app, available for download in the Apple App Store. CAVII is an iOS-based clinical study matching and analytics platform. Ushering in a new era of patient engagement, CAVII’s aim is to revolutionize clinical studies through the use of analytics for superior patient matching. Through CAVII, clinical studies could become more cost-effective, efficient and ultimately more engaging and insightful for patients and clinicians.

[Read More]

Covidien acquires Reverse Medical

Monday, August 25, 2014

Covidien, a Dublin, Ireland-based global healthcare products company and manufacturer of medical devices and supplies, has acquired California-based Reverse Medical, a privately held medical device company focused on expanding the management of vascular disease. Financial terms of the transaction have not been disclosed.

[Read More]

Medtronic to acquire Covidien for $42.9 billion

Monday, June 16, 2014

Medtronic, a global medical technology, services and solutions company, has agreed to acquire Covidien, a global healthcare technology and medical supplies provider, in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic’s closing stock price of $60.70 per share on June 13. 

[Read More]

Covidien acquires Given Imaging

Monday, December 9, 2013

Covidien, a global healthcare products company, will acquire all of the outstanding shares of Given Imaging, a provider of technology platforms for visualizing, diagnosing and monitoring the digestive system, for $30 per share in cash, for a total of approximately $860 million. Covidien intends to finance the transaction through cash on hand.

[Read More]